AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02653755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosigna
Description: Transcriptional profile of 50 genes used for risk stratification.
Study NCT02601365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim 0.04 mcg/kg/dose
Description: The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.04 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
Study NCT02601365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim 0.2mcg/kg/dose
Description: The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.2 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
Study NCT02601365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim 1 mcg/kg/dose
Description: The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 1 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
Study NCT00966446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unsupervised Decolonization
Description: Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member.
Study NCT00966446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supervised Decolonization
Description: Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member. In addition, households are contacted by study stuff via phone or text messages to ensure compliance, to provide reminders to household members to perform the decolonization protocol as well as to answer any question/concerns household members may have.
Study NCT01093573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Description: Given orally
Study NCT00285467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxercalciferol
Description: form of vitamin D that is already in active form.
Study NCT00285467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: from of vitamin D that requires cells in the body to make active
Study NCT04409054 — intervention group
Intervention type: OTHER
Intervention: Cough and Valsalva effort
Description: Three increasingly cough effort and three Valsalva type effort at four different volumes of rectal distension (empty rectum, volume for a first sensation of filling, volume for desire to defecate and maximal tolerable volume) while recording the external anal sphincter activity
Study NCT03792139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: Administered orally.
Study NCT00705640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multi-epitope melanoma peptide vaccine
Description: Given subcutaneously and intradermally
Study NCT00705640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus toxoid helper peptide
Description: Given subcutaneously and intradermally
Study NCT00705640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Patients undergo surgical biopsy at replicate vaccine site
Study NCT02482909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic resection
Description: Anatomical surgical resection of the liver including the tumor
Study NCT02482909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Percutaneous ablation using radiofrequency under the imaging guidance
Study NCT03792139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally.
Study NCT00844350 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: letrozole , oxytocin,hCG,clomiphene citrate
Study NCT03045016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin, ALPRESS® LP 2,5 et 5 mg
Description: Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):~* PERIOD 1 (Day 0 - Day 7): 1 tablet of ALPRESS LP 2.5 mg (Prazosin) at bedtime for 7 days~* PERIOD 2 (Day 8 - Day 27): 1 morning tablet of ALPRESS LP 5 mg (Prazosin) at bedtime for 21 days.
Study NCT00662896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod 375 mg bid
Description: naproxcinod 375 mg bid
Study NCT00662896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg bid
Description: naproxcinod 750 mg bid
Study NCT02420587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 208
Description: Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles.
Study NCT02420587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
Study NCT01636440 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conditioned Pain Modulation
Description: Measure of the conditioned pain modulation with the nociceptive withdrawal reflex and ice water stimulation
Study NCT01636440 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conditioned Pain Modulation
Description: Suprathreshold electrical stimulation with 1.5 times the mean electrical pain detection threshold
Study NCT01293162 — intervention group
Intervention type: DRUG
Intervention: Armolipid Prev
Description: Ortosiphon 300 mg/die, CoQ10 15 mg/die, Berberine 500 mg/die, red yeast 60 mg/die, policosanol 10 mg/die, Folic acid 200 mg/die
Study NCT00565318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benfotiamine
Description: 3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.
Study NCT00565318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3x 1 film coated tablet daily. Duration: 12 weeks.
Study NCT00723320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: atorvastatin 10mg/d
Study NCT00723320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aggressive lifestyle intervention
Description: aggressive lifestyle intervention
Study NCT04308616 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples
Study NCT02883543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: icotinib
Description: Icotinib is orally administered three times per day.
Study NCT02883543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib
Description: Icotinib is orally administered three times per day.
Study NCT02883543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy is given by intravenous administration. Three regimens are available in this study.~Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2
Study NCT02883543 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
Study NCT02883543 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
Study NCT00800371 — intervention group
Intervention type: PROCEDURE
Intervention: intra-articular steroid injection
Description: Steroid injection into otherwise noncontrollable arthritis.
Study NCT04991389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 129-Xe
Description: Inhaled contrast for MRI
Study NCT00662896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen 250 mg bid
Description: naproxen 250 mg bid
Study NCT00662896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen 500 mg bid
Description: naproxen 500 mg bid
Study NCT00662896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen 600 mg tid
Description: ibuprofen 600 mg tid
Study NCT01661517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and referral to treatment
Study NCT01728272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blood concentration of metoprolol
Description: measure blood concentration of metoprolol
Study NCT00610883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU
Description: LSA4 intervention includes three phases: induction, consolidation and maintenance
Study NCT04637659 — intervention group
Intervention type: PROCEDURE
Intervention: Root Canal Treatment
Description: Chemo-mechanical preparation will be performed using reciprocating instruments . Irrigation will be carried out with 5.25% NaOCl during instrumentation and a final flush of 17% EDTA followed by 5.25% NaOCl. After drying with paper points, canal obturation will be achieved through continuous condensation wave technique. Obturation with gutta-percha will be performed using Reciproc blue R25 master cones and root canal sealer using the BeeFill 2 in 1 device (VDW, GmbH) with a small heat carrier (#40 tip size and .03 taper) following the manufacturer's instructions. After the down-packing phase, the back-filling will be performed with the same device and manual compaction using endodontic pluggers.
Study NCT00744458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment contract
Description: Patients signs in for a agreement - to respect a regular follow-up at the health facility.
Study NCT00514007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: OSI-906 administered orally
Study NCT04238455 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham serratus anterior plane block
Description: The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.
Study NCT04238455 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.
Study NCT04188964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burosumab
Description: Burosumab is a sterile clear colourless to slightly yellow and preservative free solution supplied in single use 5ml vials containing 1 mL of Burosumab at a concentration of 10mg/mL,20 mg/mL or 30mg/mL, administered by SC injections every 2 weeks.
Study NCT02559076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ten Steps leaflet advice for healthy lifestyle
Description: Ten steps leaflet advice for healthy lifestyle
Study NCT01093573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given IV
Study NCT05328778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
Study NCT00744458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tracing and recall at home by a community worker
Description: The local health committee sends out a member to trace the patient and to motivate him to take up again regular treatment visits.
Study NCT00744458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive
Description: Incentive by giving free treatment after a 4-month regular follow-up
Study NCT03136211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EIRA intervention
Description: Individual intervention has an average intensity between 2 and 3 visits; if necessary, professionals have the freedom to make a greater number of visits. Group intervention is carried out through health education workshops. These workshops take place 15-20 days after initiating the individual intervention and they are conducted by primary care providers in the health center. A group of 12-15 people attend in each workshop. Community intervention focuses mainly on the social prescription of resources and activities that are carried out in the community where the participant person resides. In addition the intervention has the support of information and communication technologies, such as a web addressed to the participant, a mobile app or the sending personalized text messages.
Study NCT01950481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: Oral LDK378 750 mg once
Study NCT02260193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Study NCT02260193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Study NCT02260193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
Study NCT02816710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.
Study NCT03415724 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior alveolar nerve block
Description: Inferior alveolar nerve block will be given to patients having irreversible pulpitis in mandibular molars
Study NCT04174118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belcesiran
Description: belcesiran will be administered subcutaneously (SC) at dose levels planned.
Study NCT04174118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline (0.9% NaCL) matching volume of belcesiran doses will be administered subcutaneously (SC).
Study NCT01682187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally
Study NCT01682187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Administered orally
Study NCT00985751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A (formulation 1)
Description: Three doses will be administered intramuscularly, at Month 0, 2 and 6.
Study NCT00985751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A (formulation 2)
Description: Three doses will be administered intramuscularly, at Month 0, 2 and 6
Study NCT00985751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)
Description: Three doses will be administered intramuscularly, at Month 0, 2 and 6
Study NCT00985751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4)
Description: Three doses will be administered intramuscularly, at Month 0, 2 and 6
Study NCT00985751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Three doses will be administered intramuscularly, at Month 0, 2 and 6
Study NCT03681938 — intervention group
Intervention type: PROCEDURE
Intervention: Autograft
Description: Autograft
Study NCT01816360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory aromatherapy
Description: Inhalation of essential oils.
Study NCT01816360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogatherapy
Description: Yogatherapy respiratory exercises.
Study NCT05633251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variable (random) interval
Description: Using Variable (Random) Interval Reinforcement Schedules to Increase Fruit and Vegetable Intake, Reduce Fruit and Vegetable Waste, and Increase School Lunch Participation
Study NCT01397812 — intervention group
Intervention type: DEVICE
Intervention: BreathScanner 1.0
Description: For the HeartsBreath test, breath is collected using BreathScanner 1.0 and sent to central laboratory for analysis for markers of transplant rejection.
Study NCT01397812 — intervention group
Intervention type: DEVICE
Intervention: BreathLink
Description: The BreathLink point-of-care system detects and quantifies the breath VOC's determined to be biomarkers during the development of the Heartsbreath test.
Study NCT03391531 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bilateral subcostal TAP block
Description: Echo-guided infiltration of a local anesthetic solution in the plane located between the transversus abdominis muscle and the rectus abdominis muscle
Study NCT03391531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral subcostal TAP block
Description: Echo-guided infiltration of a local anesthetic solution in the plane located between the transversus abdominis muscle and the rectus abdominis muscle
Study NCT03049527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education, Incentives and Feedback
Description: The study participants will receive additional educational activities, including low-literacy fact sheets on liquid intake guidelines, cards with instructions on how to self-monitor urine color and volume, and flyers and posters placed throughout the worksite. All consenting study participants will be offered incentives to start the work day hydrated and then to maintain or improve their hydration status over the work shift. Participants who do not meet hydration goals will receive additional coaching and feedback on ways to improve hydration.Feedback will also be provided to all groups about their productivity level to help participants recognize the connection between improved health and function.
Study NCT03624829 — intervention group
Intervention type: OTHER
Intervention: Shared care
Description: The intervention is an adapted version of shared care with close collaboration by services and professional groups, mainly localized in three GP centers. At each GP center one clinical psychologist specialist from the community mental health center (CMHC) works two and a half day a week, and a psychiatrist from the CMHC work at each GP center 1-2 hours a week. The psychologist and the psychiatrist are available for the GPs for consultation and discussions, and they give assessments and brief treatments to patients as requested by the GPs. Other primary health and social care and other specialized mental health or substance addiction services are involved or consulted according to needs of the patients.
Study NCT03636737 — intervention group
Intervention type: OTHER
Intervention: pathology associated
Description: list of pathology associated to Pyoderma gangrenosum
Study NCT00515008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Intervention
Description: The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
Study NCT00515008 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Intervention
Description: Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.